Stable Cell Line Services for Assay Development

Recombinant stable cell lines are one of the widely used tools in drug discovery, toxicity testing, and basic research. Long-term stable expression of a gene of interest (GOI) is usually achieved by transfection or viral transduction of a vector containing the expression cassette of the GOI together with a selection marker (antibiotics or fluorescent proteins). In contrast to transient expression, stable cell line offers reproducible results for assay studies. Read More »
After selection, cells that have the expression cassette incorporated into the genome will be enriched, resulting in stable pool cells. By clonal selection from the stable pool cells, single clone cells are generated. Both stable pools and single clones are frequently used in research.
Recombinant stable cell line development at GenScript includes over-expression, inducible expressionI. In addition, we developed lentivirus based CRISPR/Cas (Lenti-CRISPR/Cas9) technologies and platforms, in order to meet the increasing need of knock out cell line engineering of GOI, in particular, difficult-to-transfect cancer cell lines.
Applications for these stable cell lines include but not limited to drug screening, gene expression regulations, functional assays, membrane protein antibody FACS screening, antibody immunization boosting, protein localization study by fusion with GFP and living cell imaging, and in vivo tumor xenograft models.
Stable Cell Line Services: Advantages working with GenScript CellPower™
- Multiple gene transfer methods available: Both virus (lentivirus or retrovirus) and non-virus (chemical or physical) based options
- Track record of handling difficult-to-transfect cell lines
- Experience in stably expressing membrane proteins
- High quality standards for mycoplasma control and detection
- Guaranteed mRNA expression
- Multiple functional assay methods for clone validation
- One-stop solution for drug discovery: From gene synthesis to cell development
- LentiCRISPR technology licensed from Broad Institute, Inc. Cambridge, Massachusetts
Stable Cell Line Development services by CellPower™
Service Content | Service Packages | Deliverables | Turnaround Time |
---|---|---|---|
Recombinant Expression(Over-Expression, Inducible Expression) (SC1394) | Stable Pool |
|
7-12 weeks |
Single Clone |
|
12-18 weeks | |
Lenti-CRISPR KO Service (SC1652-V) |
Lentiviral based for difficult-to-transfect cell lines |
|
16-26 Weeks |
Service | Specifications | Deliverables | Timeline |
---|---|---|---|
CellPower™ Plus | Cell pool: Use new QC standard covering more than 160 species of mycoplasma |
|
11~13 weeks (3 months) |
Single cell clone: Use new QC standard covering more than 160 species of mycoplasma |
|
15~19 weeks (4~5months) |
|
Pre-QC: GenScript will use the new QC standard to exclude potential mycoplasma contamination in host cells | QC report | 2~3 weeks |
Over-expression of GOI
![]() |
![]() |
Figure 1. PD1 expression by FACS analysis (left) and binding assay (right) in CHO-K1/PD1 cells.
Knock-down Expression of GOI
![]() |
![]() |
Figure 2. Validation of knockdown efficiency via western blotting (left) and functional assay (right).
Inducible expression of GOI
![]() |
![]() |
Figure 3. Q‐PCR (left) and western blotting (right) validation of Target A expression in HepG2 cells.
LentiCRISPR KO


Figure 4. Knockout of Target B in HepG2 cells validated by sequencing (above) and western blotting analysis (below).
Workflow of Our CellPower™ Stable Cell Line Development Process

Engineered Stable Cell Line Products
GenScript offers a wide selection of Immune Checkpoint Stable Cell Lines and GPCR Stable Cell Lines to accelerate your drug discovery. See more product introduction.
Also available are stable cell lines for protein production. See our Production Grade Stable Cell Line webpage for more details.